Does Olmesartan Medoxomil And Hydrochlorothiazide Interact with Lithium?
CDI records a major classification for Olmesartan Medoxomil And Hydrochlorothiazide and Lithium. The stored summary is: Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration. Monitor serum lithium levels during concomitant use. The mechanism involves angiotensin ii receptor antagonists and hydrochlorothiazide increase serum lithium concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Olmesartan Medoxomil And Hydrochlorothiazide Class
- Thiazide Diuretic
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Angiotensin II receptor antagonists and hydrochlorothiazide increase serum lithium concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Olmesartan Medoxomil And Hydrochlorothiazide and your doctor is considering prescribing Lithium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider